[11C]OMAR for Opioid Use Disorder

This trial aims to study how a brain receptor called CB1R functions in individuals with opioid use disorder (OUD) who are beginning opioid agonist therapy (OAT), compared to healthy individuals. The treatment uses a special imaging technique with [11C]OMAR, a radiotracer, to visualize brain activity. The trial seeks two groups: individuals seeking treatment for OUD who are ready to start buprenorphine therapy, and healthy volunteers with no history of major medical or psychiatric issues. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants an opportunity to contribute to groundbreaking research.

Research has shown that [11C]OMAR has been tested in people before. In these studies, participants generally tolerated [11C]OMAR well, with most not experiencing serious side effects. Some mild side effects occurred, but they were uncommon, and most participants felt fine after treatment. It's important to note that [11C]OMAR is currently in a Phase 1 trial, primarily focusing on its safety. So far, evidence suggests that [11C]OMAR is safe for humans, but further research is needed to confirm this.

Researchers are excited about [11C]OMAR because it offers a novel approach to understanding opioid use disorder (OUD). Unlike current standard treatments like methadone or buprenorphine that primarily work by substituting or blocking opioids, [11C]OMAR is a radiotracer used in PET scans to visualize brain activity related to opioid receptors. This unique feature helps researchers visualize and better understand the brain changes in OUD, potentially leading to more targeted therapies in the future. By providing insights into the neurological aspects of addiction, [11C]OMAR could pave the way for breakthroughs in treatment strategies.

This trial investigates how a substance called [11C]OMAR can enhance understanding of the endocannabinoid (eCB) system in individuals with opioid use disorder (OUD). The eCB system might play a role in addiction, prompting scientists to explore whether targeting it could aid in treating OUD. Although limited information exists on [11C]OMAR's effectiveness in humans, researchers are studying its potential effects on brain functions related to addiction. Early results suggest that understanding this system better could lead to new recovery support methods for OUD. Further research will determine if this approach can truly improve treatment. Participants in this trial include healthy volunteers and individuals with OUD during the early phase of opioid agonist therapy.¹²³⁴⁵